414 related articles for article (PubMed ID: 20334617)
21. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 1: triazolopyrimidine, isoxazolopyrimidine and pyrrole-based (DSM) compounds.
Sharma M; Pandey V; Poli G; Tuccinardi T; Lolli ML; Vyas VK
Bioorg Chem; 2024 May; 146():107249. PubMed ID: 38493638
[TBL] [Abstract][Full Text] [Related]
23. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Deng X; Kokkonda S; El Mazouni F; White J; Burrows JN; Kaminsky W; Charman SA; Matthews D; Rathod PK; Phillips MA
J Med Chem; 2014 Jun; 57(12):5381-94. PubMed ID: 24801997
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
Heikkilä T; Ramsey C; Davies M; Galtier C; Stead AM; Johnson AP; Fishwick CW; Boa AN; McConkey GA
J Med Chem; 2007 Jan; 50(2):186-91. PubMed ID: 17228860
[TBL] [Abstract][Full Text] [Related]
25. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.
Coteron JM; Marco M; Esquivias J; Deng X; White KL; White J; Koltun M; El Mazouni F; Kokkonda S; Katneni K; Bhamidipati R; Shackleford DM; Angulo-Barturen I; Ferrer SB; Jiménez-Díaz MB; Gamo FJ; Goldsmith EJ; Charman WN; Bathurst I; Floyd D; Matthews D; Burrows JN; Rathod PK; Charman SA; Phillips MA
J Med Chem; 2011 Aug; 54(15):5540-61. PubMed ID: 21696174
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
Molecules; 2018 May; 23(6):. PubMed ID: 29794978
[TBL] [Abstract][Full Text] [Related]
27. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance.
Lukens AK; Ross LS; Heidebrecht R; Javier Gamo F; Lafuente-Monasterio MJ; Booker ML; Hartl DL; Wiegand RC; Wirth DF
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):799-804. PubMed ID: 24381157
[TBL] [Abstract][Full Text] [Related]
28. Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase.
Marwaha A; White J; El Mazouni F; Creason SA; Kokkonda S; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2012 Sep; 55(17):7425-36. PubMed ID: 22877245
[TBL] [Abstract][Full Text] [Related]
29. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
30. Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.
Ross LS; Lafuente-Monasterio MJ; Sakata-Kato T; Mandt REK; Gamo FJ; Wirth DF; Lukens AK
ACS Infect Dis; 2018 Apr; 4(4):508-515. PubMed ID: 29336544
[TBL] [Abstract][Full Text] [Related]
31. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Patel V; Booker M; Kramer M; Ross L; Celatka CA; Kennedy LM; Dvorin JD; Duraisingh MT; Sliz P; Wirth DF; Clardy J
J Biol Chem; 2008 Dec; 283(50):35078-85. PubMed ID: 18842591
[TBL] [Abstract][Full Text] [Related]
33. Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase.
Krungkrai J; Krungkrai SR; Phakanont K
Biochem Pharmacol; 1992 Mar; 43(6):1295-301. PubMed ID: 1348618
[TBL] [Abstract][Full Text] [Related]
34. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors.
Tseng TS; Lee YC; Hsiao NW; Liu YR; Tsai KC
Bioorg Med Chem Lett; 2016 Jan; 26(2):265-271. PubMed ID: 26707392
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of the mitochondrial electron transport chain and de novo pyrimidine biosynthesis as antimalarials: The present status.
Rodrigues T; Lopes F; Moreira R
Curr Med Chem; 2010; 17(10):929-56. PubMed ID: 20156168
[TBL] [Abstract][Full Text] [Related]
36. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Palmer MJ; Deng X; Watts S; Krilov G; Gerasyuto A; Kokkonda S; El Mazouni F; White J; White KL; Striepen J; Bath J; Schindler KA; Yeo T; Shackleford DM; Mok S; Deni I; Lawong A; Huang A; Chen G; Wang W; Jayaseelan J; Katneni K; Patil R; Saunders J; Shahi SP; Chittimalla R; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Tumwebaze PK; Rosenthal PJ; Cooper RA; Aguiar ACC; Guido RVC; Pereira DB; Mittal N; Winzeler EA; Tomchick DR; Laleu B; Burrows JN; Rathod PK; Fidock DA; Charman SA; Phillips MA
J Med Chem; 2021 May; 64(9):6085-6136. PubMed ID: 33876936
[TBL] [Abstract][Full Text] [Related]
37. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Baldwin J; Michnoff CH; Malmquist NA; White J; Roth MG; Rathod PK; Phillips MA
J Biol Chem; 2005 Jun; 280(23):21847-53. PubMed ID: 15795226
[TBL] [Abstract][Full Text] [Related]
38. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.
Mandt REK; Luth MR; Tye MA; Mazitschek R; Ottilie S; Winzeler EA; Lafuente-Monasterio MJ; Gamo FJ; Wirth DF; Lukens AK
Elife; 2023 Sep; 12():. PubMed ID: 37737220
[TBL] [Abstract][Full Text] [Related]
39. Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones.
Clark RD; Morris DN; Chinigo G; Lawless MS; Prudhomme J; Le Roch KG; Lafuente MJ; Ferrer S; Gamo FJ; Gadwood R; Woltosz WS
J Comput Aided Mol Des; 2020 Nov; 34(11):1117-1132. PubMed ID: 32833084
[TBL] [Abstract][Full Text] [Related]
40. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
